Bifogade filer
PDF
Kurs & Likviditet
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Today, the annual general meeting of 2021 was held in OssDsign AB (publ). Below is a summary of the resolutions passed at the annual general meeting (all in accordance with the proposals presented in the notice to attend the meeting kept available at the company's website www.ossdsign.com).
to adopt the profit and loss statement and the balance sheet and the group profit and loss statement and the group balance sheet for the financial year 2020;
that the company's accumulated profits shall be carried forward in new account and that no dividend shall be paid;
to grant the board members and the CEO discharge from liability for the financial year 2020;
that the board of directors shall consist of five ordinary members without deputy members, to re-elect all current board members (Simon Cartmell, Anders Qvarnström, Håkan Engqvist, Newton Aguiar and Viktor Drvota), and to re-elect Simon Cartmell as chairman of the board;
that a registered accounting firm shall be elected as auditor and to re-elect KPMG AB as the company's auditor;
that fees payable to the board members until the end of the next annual general meeting shall amount to a total of SEK 1,000,000 out of which SEK 350,000 shall be paid to the chairman, SEK 250,000 to each of Anders Qvarnström and Newton Aguiar and SEK 150,000 to Håkan Engqvist;
that fees payable to the auditor is to be paid in accordance with approved invoices;
on an authorization for the board of directors to increase the share capital through issuance of new shares, warrants and/or convertible debentures through which the company's share capital may be increased by an amount corresponding to not more than 10 per cent of the share capital after such issue(s);
on a long-term incentive programme for employees and contractors by way of a directed issue of no more than 3,024,945 warrants (each warrant giving right to subscribe for one new share during the period as from and including 1 July 2024 until and including 31 December 2024) and approval of transfer of warrants to participants in the programme; and
on a long-term incentive programme for board members by way of a directed issue of no more than
799,041 warrants (each warrant giving right to subscribe for one new share during the period as from and including 1 July 2024 until and including 31 December 2024) and approval of transfer of warrants to participants in the programme.
For further information, please contact:
Morten Henneveld, CEO, OssDsign AB
Mob: +46 73 382 43 90
morten.henneveld@ossdsign.com
Certified Adviser:
Erik Penser Bank AB is the Company's Certified Adviser. Contact information: Erik Penser Bank AB, Box 7405, 103 91 Stockholm, Sweden, phone: +46 (0)8-463 80 00, email: certifiedadviser@penser.se.
The information was submitted for publication, through the agency of the contact persons set out above, on 22 June 2021, 13:30 CET.
About OssDsign
OssDsign's vision is to provide regenerative solutions to all patients with cranial or spinal bone defects, so they can be restored and healed as naturally as possible. Driven by a commitment to give patients back the lives they deserve, OssDsign collaborates with surgeons to engineer better healing by integrating biomaterials with clinical design. Headquartered in Sweden, OssDsign supplies hospitals worldwide with implants for use in cranial reconstructions and other orthopaedic surgery applications. OssDsign (OSSD) is listed on First North since May 24, 2019. For more information, see http://www.ossdsign.com